Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIG-1 AML phase II/III randomized study
2024-516873-57-00Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax and cytarabine in acute myeloid leukemia (AML) (7 arms), sponsored by Centre Hospitalier Universitaire d'Angers. Primary endpoints: Overall survival at 3 years for R1, Overall survival at 3 years for R2 and 1 more. Started Jan 2026; status: completed.
02
Drugs
venetoclaxcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-516873-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516873-57-00.